



REVERSE WP5 – IMPLEMENTATION

Prof Lauren Clack; Dr Bianca Albers; Laura Caci – Institute for Implementation Science in Health Care, UZH



Our WP5 Team



Prof. Lauren Clack
WP5 Leader



Dr. Bianca Albers
Postdoctoral Researcher



Laura Caci
PhD Candidate



Dr. Peter Brauchli
Administrative Contact



WP5 – Central research question

**Will the tailored
implementation of
REVERSE clinical
interventions (IPC &
ABS) be superior to a
standard approach to
their implementation?**





WP5 – Focus: Implementation strategies & their tailoring


Implementation strategies: “Methods or techniques used to enhance the adoption, implementation, and sustainability of a clinical program or practice.” (Proctor et al., 2013)

- ‘How to’ component of change
- Examples of implementation strategies: Training; audit & feedback; utilisation of ‘champions’
- ERIC – Expert Recommendations for Implementing Change – taxonomy (Powell et al., 2015) represents consensus on common implementation strategy terms, definitions and categories and will be utilised

Tailored implementation strategies: “Strategies to improve professional practice that are *planned, taking account of prospectively identified determinants of practice.*” (Baker, 2015)

- Examples of determinants: Organisational culture, climate, resources, structures; provider knowledge, motivation, perception; legislative foundations, policy agendas; patient factors
- CFIR – the Consolidated Framework for Implementation Research (Damschroder et al., 2009) will be used

Consolidated Framework for Implementation Research (CFIR)





WP5 – Objectives

1. To understand **contextual barriers and facilitators** for the implementation of antibiotic stewardship, diagnostic stewardship and infection prevention and control measures in acute care hospitals in regions with high antimicrobial resistance prevalence;
2. To develop **generalisable knowledge** about the determinants influencing implementation of IPC, ABS and MDS practices in a diverse group of European hospitals;
3. To design and evaluate a **tailored implementation strategy** as compared with a standard implementation strategy as part of a type 2 hybrid implementation-effectiveness trial;
4. To **produce tools for implementing** antibiotic stewardship and infection prevention and control, taking into account organisational culture, national strategies, and the hospital networks along their referral pathways;
5. To **engage regional and national stakeholders** in healthcare and politics to engage in antibiotic stewardship and infection prevention and control.



WP5 - Tasks

- Task 5.1: Organisational culture and readiness for implementation of the REVERSE hospitals (month 6 – 18)
- Task 5.2: Prospective identification of implementation determinants and development of tailored implementation strategies in ENHANCE study sites (month 12 – 24)
- Task 5.3: Training local implementation teams/onsite investigators (month 18 – 36)
- Task 5.4: Formative evaluation of implementation process in ENHANCE study sites (month 24 – 48)
- Task 5.5: Summative evaluation (month 48 – 60)
- Task 5.6: Tools for capacity building (month 36 – 60)
- Task 5.7: Networking and sustainability (month 12 – 40, 51)



WP5 – Linkages with and questions to discuss with other WPs

– WP 1

- Linkages: Joint conduct of readiness assessments; determinant identification; training of implementation teams; summative evaluation; capacity building & network development
- Questions: Can the measurement of selected implementation outcomes (e.g., feasibility, acceptability, fidelity) be integrated into our list of secondary outcomes?

– WP 3 (IPC) and WP 4 (ABS)

- Linkage: We will support the implementation of interventions developed by WP 3&4
- Questions: What will be the key components of each intervention? What will their implementation require? Will it be possible to tailor the interventions?

– WP 6

- Linkage: We want to understand the costs of tailored implementation
- Questions: How can the cost efficiency/ effectiveness of tailoring be monitored and measured?

– WP 8 (ethics)

- Linkage: Our data collection will need to be sufficiently captured in our study protocol
- Questions: How will we develop a joint protocol to include all study details? And how will we register and publish this protocol as a group?



Any questions?



REVERSE has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 965265. This presentation reflects only the author's view and the Commission is not responsible for any use that may be made of the information it contains